IFNA17 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, HHT has been shown to reduce the expression level of the p210BCR‐ABL protein in BCR‐ABL + cells, thus emerging as an effective treatment for CML patients who are unresponsive to IFN-α therapy [7].